Advent Life Sciences Amends Eloxx Pharma Stake

TL;DR

Advent Life Sciences Fund II LP just updated their Eloxx Pharma (ELOX) filing. Watch this space.

AI Summary

Advent Life Sciences Fund II LP, along with Dominic Schmidt, Kaasim Mahmood, Rajesh Parekh, and Shahzad Malik, filed an amendment (SC 13D/A) on August 20, 2024, regarding their holdings in Eloxx Pharmaceuticals, Inc. The filing indicates a change in their beneficial ownership, though specific new percentage or dollar amounts are not detailed in this excerpt. This amendment updates previous filings concerning their investment in the company.

Why It Matters

This filing signals a potential shift in control or strategy for Eloxx Pharmaceuticals, as a significant investor has updated their disclosure. Investors will monitor future actions for clues about the company's direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in investor sentiment or strategy, potentially impacting the stock price.

Key Players & Entities

• Advent Life Sciences Fund II LP (company) — Filing entity
• Dominic Schmidt (person) — Group member
• Kaasim Mahmood (person) — Group member
• Rajesh Parekh (person) — Group member
• Shahzad Malik (person) — Group member
• Eloxx Pharmaceuticals, Inc. (company) — Subject company
• Advent Life Sciences LLP (company) — Filing entity

FAQ

Key Financial Figures

• $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class o

Filing Documents

• formsc13da.htm (SC 13D/A) — 98KB
• exhibit1.htm (EX-1) — 6KB
• exhibit1xz001.jpg (GRAPHIC) — 2KB
• exhibit1xz002.jpg (GRAPHIC) — 2KB
• exhibit1xz003.jpg (GRAPHIC) — 2KB
• exhibit1xz004.jpg (GRAPHIC) — 2KB
• exhibit1xz005.jpg (GRAPHIC) — 3KB
• exhibit1xz006.jpg (GRAPHIC) — 2KB
• formsc13daxu001.jpg (GRAPHIC) — 2KB
• formsc13daxu002.jpg (GRAPHIC) — 2KB
• formsc13daxu003.jpg (GRAPHIC) — 2KB
• formsc13daxu004.jpg (GRAPHIC) — 2KB
• formsc13daxu005.jpg (GRAPHIC) — 3KB
• formsc13daxu006.jpg (GRAPHIC) — 2KB
• 0001062993-24-015470.txt ( ) — 142KB

Identity and Background

Item 2. Identity and Background (a) The Reporting Persons are: 1. Advent Life Sciences LLP ("Advent") 2. Advent Life Sciences Fund II LP (the "Advent Fund") 3. Rajesh Parekh 4. Shahzad Malik 5. Kaasim Mahmood 6. Dominic Schmidt (b) The principal business office of each of the Reporting Persons and Advent Life Sciences GP LLP, the general partner of the Advent Fund ("Advent GP") is located at 27 Fitzroy Square, London W1T 6ES, United Kingdom. (c) Advent and the Advent Fund are entities engaged in investment activities; Advent also is in the business of acting as the manager of the Advent Fund and a member of Advent GP. Advent GP is the general partner of the Advent Fund. The principal business of Dr. Parekh, Dr. Malik, Dr. Mahmood, and Dr. Schmidt are to serve as general partners of Advent and engage in other investment activities. Dr. Parekh previously served as a member of the Issuer's board of directors (the "Board") until July 1, 2022 and is a member of boards of directors of other private and public companies. Dr. Malik, Dr. Mahmood, and Dr. Schmidt are also members of the board of directors of various private and public companies. (d) None of the Reporting Persons nor Advent GP, during the last five years, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) None of the Reporting Persons nor Advent GP, during the last five years, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Each of Advent and Advent GP is a limited liability partnership organized under the laws of the United Kingdom. The Advent Fund is a limited partnership organized under the laws of the United Kingdom. Each of Dr. Pa

Interest in Securities of the Issuer

Item 3. Interest in Securities of the Issuer (a) Items 7 through 11 and 13 of each of the cover pages of this statement on Schedule 13D are incorporated herein by reference. All percentages of ownership of Common Stock by the Reporting Persons in this statement on Schedule 13D assume an aggregate of 3,143,390 shares of common stock outstanding, no shares of preferred stock outstanding, and warrants to purchase 404,446 shares of common stock, options to purchase 315,552 shares of common stock, and restricted stock units for 75,000 shares of common stock were outstanding as of December 31, 2023, as reported by the Issuer on the Form S-3 Registration Statement filed with the Securities and Exchange Commission by the Issuer on January 24, 2024. (b) Items 7 through 11 and 13 of each of the cover pages of this statement on Schedule 13D are incorporated herein by reference. The Reporting Persons disclaim beneficial ownership of the securities held by each of the other Reporting Persons, and this statement on Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any such Reporting Persons actually exercise voting or dispositive power with respect to such securities. (c) The information set forth in Item 3 is hereby incorporated by reference. None of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days. (d) Except as set forth herein, no other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Ordinary Shares beneficially owned by the Reporting Persons. (e) This amendment is being filed to disclose that, as of January 25, 2024, the Reporting Persons no longer beneficially own more than five percent of the outstanding Common Stock of the Issuer

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 4. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer The information in Item 3 is hereby incorporated herein by reference.

Material to Be Filed as Exhibits

Item 5. Material to Be Filed as Exhibits Exhibit Description I Agreement Regarding the Joint Filing of Schedule 13D/A by and among the Reporting Persons, dated as of August 20, 2024. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: August 20, 2024 ADVENT LIFE SCIENCES LLP By: Rajesh Parekh, General Partner of Advent Life Sciences LLP ADVENT LIFE SCIENCES FUND II LP By: Rajesh Parekh, General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund II LP RAJESH PAREKH SHAHZAD MALIK KAASIM MAHMOOD DOMINIC SCHMIDT The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

View Full Filing

View this SC 13D/A filing on SEC EDGAR